Once-daily therapies for the treatment of HIV infection (Q36445654)

14 August 2017

1 reference

title

Once-daily therapies for the treatment of HIV infection (English)

1 reference

14 August 2017

Karen T Tashima

1

1 reference

14 August 2017

Jennifer Adelson Mitty

series ordinal

2

1 reference

14 August 2017

language of work or name

1 reference

1 July 2006

1 reference

14 August 2017

published in

Current HIV/AIDS reports

1 reference

14 August 2017

volume

3

1 reference

14 August 2017

issue

2

1 reference

14 August 2017

page(s)

86-92

1 reference

Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals

14 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11904-006-0023-0

Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine

21 January 2018

1 reference

12 December 2020

Effectiveness and tolerability of a once-daily amprenavir/ritonavir-containing highly active antiretroviral therapy regimen in antiretroviral-naïve patients at risk for nonadherence: 48-week results after 24 weeks of directly observed therapy

1 reference

12 December 2020

Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence

1 reference

12 December 2020

The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy

1 reference

12 December 2020

Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen

1 reference

12 December 2020

The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: implications for once-daily dosing

1 reference

12 December 2020

Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial

1 reference

12 December 2020

A longitudinal analysis of hospitalization and emergency department use among human immunodeficiency virus-infected women reporting protease inhibitor use.

1 reference

12 December 2020

Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial

1 reference

12 December 2020

Impact of once- and twice-daily dosing regimens on adherence and overall safety

1 reference

12 December 2020

Long-term utility of measuring adherence by self-report compared with pharmacy record in a routine clinic setting

1 reference

12 December 2020

Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures

1 reference

12 December 2020

Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load

1 reference

12 December 2020

Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study.

1 reference

12 December 2020

Enhancing adherence to HAART: a pilot program of modified directly observed therapy

1 reference

12 December 2020

Editorial comment: thoughts on the once-daily-dosing bandwagon

1 reference

12 December 2020

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

1 reference

12 December 2020

CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related.

1 reference

12 December 2020

Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial

1 reference

12 December 2020

Higher rates of viral suppression with nonnucleoside reverse transcriptase inhibitors compared to single protease inhibitors are not explained by better adherence

1 reference

12 December 2020

Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects

1 reference

12 December 2020

Adherence to protease inhibitor therapy and outcomes in patients with HIV infection

1 reference

12 December 2020

Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: implications for program replication

1 reference

12 December 2020

Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies

1 reference

12 December 2020

Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults

1 reference

12 December 2020

High rate of virological failure in maintenance antiretroviral therapy with didanosine and tenofovir

1 reference

12 December 2020

The importance of potency and durability in HIV patient antiretroviral therapy preferences: a telephone survey

1 reference

12 December 2020

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

1 reference

12 December 2020

Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients.

1 reference

12 December 2020

Rapid viral load suppression following generic highly active antiretroviral therapy in Southern Indian HIV-infected patients

1 reference

12 December 2020

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial

1 reference

12 December 2020

The use of community-based modified directly observed therapy for the treatment of HIV-infected persons

1 reference

12 December 2020

Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial.

1 reference

12 December 2020

Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules

1 reference

12 December 2020

10.1007/S11904-006-0023-0

Identifiers

DOI

1 reference

14 August 2017

1 reference